|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
18 April 2017 |
|
Main ID: |
ChiCTR-TRC-12002416 |
|
Date of registration:
|
2012-08-13 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Research on the Association between rs5911, rs5787 and rs3842788 Gene Polymorphisms and the Effect of Activating Blood and Removing Stasis Herbs in Coronary Heart Disease Patients with Aspirin Resistance
|
|
Scientific title:
|
Research on the Association between Aspirin Resistance, rs5911, rs5787 and rs3842788 Gene Polymorphisms, and the Effect of Activating Blood and Removing Stasis Herbs |
|
Date of first enrolment:
|
2012-08-28 |
|
Target sample size:
|
Chinese herb medicine group:30;Control:30; |
|
Recruitment status: |
Completed |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=7134 |
|
Study type:
|
Interventional study |
|
Study design:
|
Randomized parallel controlled trial
|
|
Phase:
|
Post-market
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Mei Xue
|
|
Address:
|
1 Xiyuan Chaochang, Haidian district, Beijing
|
|
Telephone:
|
+86 13581801296 |
|
Email:
|
meiar@126.com |
|
Affiliation:
|
|
|
|
Name:
|
Mei Xue
|
|
Address:
|
1 Xiyuan Chaochang, Haidian district, Beijing
|
|
Telephone:
|
+86 13581801296 |
|
Email:
|
meiar@126.com |
|
Affiliation:
|
Xiyuan Hospital, China Academy of Chinese Medicine |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Stable angina: (Chinese Journal of Cardiology. 2007; 35: 159-206);
2. Aged 35 to 75 years old;
3. Have taken aspirin for more than 7 days;
4. Aspirin resistance:
(1) platelet aggregation rate >=70% when diphosphate adenosine (concentration 10uM) induced;
(2) platelet aggregation rate >=20% when arachidonic acid (concentration 0.5mg/ml) induced.
Exclusion criteria: 1. Aspirin allergy;
2. Family or personal history of bleeding disorders;
3. platelet count<100*10^9/L, or >450*10^9/L;
4. Hemoglobin <90g/L;
5. Have taken other antiplatelet, anticoagulant drugs or non-steroidal anti-inflammatory drugs, that may affect platelet aggregation, such as clopidogrel, ticlopidine, warfarin or heparin in latest two weeks;
6. Have taken activating blood and removing stasis herbs in latest two weeks;
7. History of trauma or surgery in latest two weeks;
8. With severe primary diseases of hepatic, renal, hematopoietic and nervous system, mental disorder or malignant tumor;
9. Woman in Pregnancy, or lactation period.
Age minimum:
Age maximum:
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Coronary Heart Disease (CHD)
|
|
Intervention(s)
|
|
Chinese herb medicine group:Conventional therapy combine with activating blood and removing stasis herbs ;Control:Conventional therapy combine with routine treatment for four weeks ;
|
|
Primary Outcome(s)
|
|
Gene polymorphisms;Platelet aggregation rate;
|
|
Source(s) of Monetary Support
|
|
National Natural Science Foundation
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|